Comment on

• Cholesterol-lowering therapy for primary prevention: still much we don't know.

  Green LA. Green LA. Arch Intern Med. 2010 Jun 28;170(12):1007-8. doi: 10.1001/archinternmed.2010.168. Arch Intern Med. 2010. PMID: 20585062 No abstract available.
• Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.

  Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Ray KK, et al. Arch Intern Med. 2010 Jun 28;170(12):1024-31. doi: 10.1001/archinternmed.2010.182. Arch Intern Med. 2010. PMID: 20585067 Review.
• Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

  de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.
• By Jove! What is a clinician to make of JUPITER?

  Kaul S, Morrissey RP, Diamond GA. Kaul S, et al. Arch Intern Med. 2010 Jun 28;170(12):1073-7. doi: 10.1001/archinternmed.2010.189. Arch Intern Med. 2010. PMID: 20585074 Review. No abstract available.